[Clinical evaluation of a new antianginal drug: droprenylamine].
In this study the antianginal action of droprenylamine, a cycloaliphatic derivative of prenylamine, was evaluated. Forty patients were included in three groups: in the first group a double blind study was carried out, while in the other two groups, both treated with droprenylamine for a 12 weeks period, were evaluated the effects on workload tolerance or the efficacy in reducing the number of angina pectoris episodes per week and the assumption of nitroglycerine. The double blind study shows that droprenylamine is able to reduce significantly the nitroglycerine assumption. Furthermore, during the 12 week treatment with droprenylamine we can observe a significant reduction of the ST segment depression, at comparable workloads, a significantly increased tolerance to stress test and an early and significant reduction of the angina attacks and, subsequently, of the assumption of nitroglycerine. In conclusion, this drug, which appears free of side effects, may be useful in the treatment of angina pectoris; in particular, the possible association with other antianginal drugs should be evaluated.
D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D004311:Double-Blind Method; D005080:Exercise Test; D006801:Humans; D008875:Middle Aged; D011299:Prenylamine / Q000031:analogs & derivatives; D011897:Random Allocation; D013997:Time Factors
C013771:droprenylamine; D011299:Prenylamine
Valutazione clinica di un nuovo farmaco antianginoso: la droprenilamina.